RxDoctor Payments Data

Bruni Leka, DPM

Primary Podiatric Medicine · Philadelphia, PANPI 1689014425

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Smith+Nephew at 34.0% of the total.

$734in general payments, 2019–2025

Across 24 payments — averaging $30.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$250
  • Paratek Pharmaceuticals, Inc.$213
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$71
  • International Rehabilitative Sciences, Inc$40
  • Reprise Biomedical, Inc.$33
  • Next Science LLC$24
  • plus $103 from 6 others

What the payments were for

  • Food & beverage$734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$734 in reported general payments places this provider in the 60th percentile of 31 primary podiatric medicine providers in Pennsylvania.

See all primary podiatric medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$113,117
Medicare patients
270
Services billed
1,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole18$14,472
Ammonium Lactate391$5,418
Ciclopirox184$3,837
Gabapentin130$1,465
Betamethasone Dipropionate26$1,134
SsdSilver Sulfadiazine21$786
Meloxicam63$562
Mupirocin47$435
Terbinafine Hcl47$380
Silver Sulfadiazine21$355
Pregabalin41$328
Cephalexin18$123
Diclofenac Sodium13$116
Lidocaine15$81
Hydrocortisone11$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$71$14,47218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 31 primary podiatric medicine providers in Pennsylvania.

Other primary podiatric medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →